New agents for the treatment of gout and hyperuricemia: febuxostat, puricase, and beyond.
The rising prevalence of gout has led the pharmaceutical industry to rediscover what it had considered a forgotten disease. In April 2009, the Food and Drug Administration (FDA) approved febuxostat (Takeda Pharmaceuticals; Deerfield, IL), the first new urate-lowering gout drug in more than 40 years. In August 2009, the FDA approved colchicine for the treatment of acute gout. Several other pharmaceutical companies are also conducting clinical trials to test new drugs for acute and chronic gout. This article reviews new drugs and drugs in development in the management of acute and chronic gout.
Schlesinger
Naomi
N
Division of Rheumatology, Department of Medicine, University of Medicine and Dentistry of New Jersey/Robert Wood Johnson Medical School, One Robert Wood Johnson Place, New Brunswick, NJ 08903, USA. schlesna@umdnj.edu
D000208:Acute Disease; D002908:Chronic Disease; D003078:Colchicine / Q000627:therapeutic use*; D000069465:Febuxostat; D006073:Gout / Q000188:drug therapy*; D006074:Gout Suppressants / Q000627:therapeutic use*; D006801:Humans; D033461:Hyperuricemia / Q000188:drug therapy*; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D013844:Thiazoles / Q000627:therapeutic use*; D014503:Urate Oxidase / Q000627:therapeutic use*
D006074:Gout Suppressants; D013844:Thiazoles; D000069465:Febuxostat; D011092:Polyethylene Glycols; D014503:Urate Oxidase; C031545:Pegloticase; D003078:Colchicine